NCT03878823: Safety and Pharmacokinetics of ODM-209

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Endocrine (Hormone Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have disease progression after treatment with 2 lines of systemic treatment for MBC (one line must have been endocrine treatment plus a CDK4/6 inhibitor)
Exclusions: Patients with known brain metastases or active leptomeningeal disease

Comments are closed.

Up ↑